UBS Group’s Sinovac Biotech, Ltd SVA Stock Holding History

UBS Group’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-200	Closed	-$1K	–	10256
2014 Q4	$1K	Buy	+200	New	+$1.02K	﹤0.01%	9654

Other funds holding SVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

UBS Group's SVA Position: Q1 2026 in Review

UBS Group reduced its Sinovac Biotech, Ltd (SVA) stake by 76% in Q1 2026, selling an estimated $45.2K and leaving 2,229 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #8170.

UBS Group first reported a position in SVA in Q4 2014 and has held it in 37 quarters since. The position peaked at $66K in Q1 2018. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

UBS Group held 2,229 shares of Sinovac Biotech, Ltd worth $14.4K as of Q1 2026.
UBS Group sold 6,993 Sinovac Biotech, Ltd shares in Q1 2026, an estimated $45.2K.
Sinovac Biotech, Ltd made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8170 holding.
UBS Group first reported a position in Sinovac Biotech, Ltd in Q4 2014 and has held it in 37 quarters since.
UBS Group's Sinovac Biotech, Ltd position peaked at $66K in Q1 2018.
28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.